Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

We recently published a list of 12 Best Quality Stocks to Invest in Now. In this article, we are going to take a look at ...

On Feb. 27, Blackstone disclosed that Rodney Zemmel – a long-time Senior Partner at McKinsey, who served as the global leader of both McKinsey Digital and the firm’s AI Transformation initiatives – ...

We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...

US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

AN ALZHEIMER’S drug hailed as a ‘miracle’ medicine for dementia may cause life-threatening brain bleeds in a third of ...

Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?

Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Eli Lilly and AstraZeneca (AZ) have said they are to co-develop a potentially disease-modifying treatment for Alzheimer's disease (AD), in the aftermath of the high-profile failure of a Lilly ...

A so-called 'miracle' Alzheimer's drug caused brain bleeds in more than a third of patients, a new study has revealed.